The Future of GDNF in Parkinson's Disease

Fredric P Manfredsson; Nicole K Polinski; Thyagarajan Subramanian; Nicholas Boulis; Dustin R Wakeman; Ronald J Mandel

doi:10.3389/fnagi.2020.593572

The Future of GDNF in Parkinson's Disease

Front Aging Neurosci. 2020 Dec 7;12:593572. doi: 10.3389/fnagi.2020.593572. eCollection 2020.

Authors

Fredric P Manfredsson¹, Nicole K Polinski², Thyagarajan Subramanian³, Nicholas Boulis⁴, Dustin R Wakeman^{5

6}, Ronald J Mandel⁷

Affiliations

¹ Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, United States.
² The Michael J. Fox Foundation for Parkinson's Research, New York, NY, United States.
³ Department of Neurology and Neural and Behavioral Sciences, Penn State University College of Medicine, Hershey, PA, United States.
⁴ Department of Neurosurgery, Emory University, Atlanta, GA, United States.
⁵ Virscio, Inc., New Haven, CT, United States.
⁶ Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States.
⁷ Department of Neuroscience, University of Florida, Gainesville, FL, United States.

No abstract available

Keywords: GDNF (glial cell line-derived neurotrophic factor); Parkinson's disease; clinical trial (2.172); gene therapy (GT); neurotrophic factor; neurturin.